SCHEMBL6130149

SCHEMBL6130149

COC1=CC=C(Cl)C[CH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2397826 0.64
SCHEMBL6845565 0.62
SCHEMBL12502146 0.61 P2RX7 (0.40)
SCHEMBL752148 0.59
SCHEMBL14458792 0.59
SCHEMBL1921548 0.56
SCHEMBL17398305 0.55
SCHEMBL646232 0.55
SCHEMBL1590471 0.55
SCHEMBL1589682 0.55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018157046-A1 METHODS OF TREATING SEIZURE DISORDERS OVID THERAPEUTICS INC. (US) 2018-08-30 WO claimed
EP-2723336-A1 COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME Centre National De La Recherche Scientifique (FR) 2014-04-30 EP claimed
WO-2013001412-A1 COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-01-03 WO claimed
EP-1330426-A4 SELECTIVE MAXI-K- POTASSIUM CHANNEL OPENERS FUNCTIONAL UNDER CONDITIONS OF HIGH INTRACELLULAR CALCIUM CONCENTRATION, METHODS AND USES THEREOF BRISTOL MYERS SQUIBB CO (US) 2005-09-14 EP claimed
EP-1330426-A1 SELECTIVE MAXI-K- POTASSIUM CHANNEL OPENERS FUNCTIONAL UNDER CONDITIONS OF HIGH INTRACELLULAR CALCIUM CONCENTRATION, METHODS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-30 EP claimed
WO-2002030868-A1 SELECTIVE MAXI-K- POTASSIUM CHANNEL OPENERS FUNCTIONAL UNDER CONDITIONS OF HIGH INTRACELLULAR CALCIUM CONCENTRATION, METHODS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2002-04-18 WO claimed
WO-2018157046-A1 METHODS OF TREATING SEIZURE DISORDERS OVID THERAPEUTICS INC. (US) 2018-08-30 WO disclosed
EP-2723336-A1 COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME Centre National De La Recherche Scientifique (FR) 2014-04-30 EP disclosed
WO-2013001412-A1 COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-01-03 WO disclosed